Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...

Experts across healthcare debunk 15 common myths about GLP-1 medications—covering everything from access and cost to ...

Real Housewives of New Jersey” star Jennifer Fessler didn’t follow her doctor’s advice when she started taking a GLP-1 weight ...

Novo Nordisk is shaking up its executive team as it bids adieu to its longtime head of commercial strategy and corporate ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

In the realm of investing, finding value in mega-cap stocks can often seem like searching for a needle in a haystack. Nvidia ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

In this photo illustration, the injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...